Psoriasis: aspectos comparativos entre la edad pediátrica y adulta de interés para el médico general
DOI:
https://doi.org/10.17696/2318-3691.27.1.2020.1622Palavras-chave:
Psoriasis; TerapéuticaResumo
Introducao: La psoriasis es una enfermedad sistémica con alto impacto en la calidad de vida, afecta 1 a 2% de la población general y puede iniciarse en el lactante o debutar en la infancia, adolescencia o adultez. Dependiendo de la edad, las características clínicas varían y, por tanto, el tratamiento es diferente. Objetivo: Transmitir al médico general aspectos comparativos útiles para su práctica diaria, que le permitan un abordaje inicial y un manejo interdisciplinario de la psoriasis. Resultados: El 27% de los casos se manifiesta antes de los 15 años con placas delgadas o gotas, con localización retroauricular, facial, umbilical o en el área del pañal, lo que puede retrasar el diagnóstico. Dependiendo de la edad, localización y extensión de las lesiones, los tratamientos tópicos y la fototerapia UVB nb son de elección en las formas leves a moderadas en los niños y adultos, por ser seguros y efectivos, los sistémicos y biológicos se reservan para formas severas, artropáticas, por el potencial riesgo de efectos adversos. Conclusao: Tanto el manejo inicial para mejorar la barrera de la piel como los tratamientos tópicos pueden ser realizados por el médico generalista, de forma interdisciplinaria. Para casos con formas clínicas más complejas y comorbilidades, el manejo debe ser más intensivo. Las formas severas sub tratadas afectan la calidad de vida.
Referências
Bronckers IMGJ, Paller AS, van Geel MJ, van de Kerkhof PCM, Seyger MMB. Psoriasis in Children and Adolescents: Diagnosis, Management and Comorbidities. Paediatr Drugs. 2015;17: 373–384.
Website. [cited 24 Sep 2020]. Available: Romiti R, Maragno L, Arnone M, Takahashi MDF. Psoríase na infância e na adolescência. An Bras Dermatol. 2009;84(1):9-22. https://doi.org/10.1590/S0365-05962009000100002
Oostveen AM, Bergboer JGM, van de Kerkhof PCM, Zeeuwen PLJM, de Jong EMGJ, Schalkwijk J, et al. Genotype-phenotype correlations in a prospective cohort study of paediatric plaque psoriasis: lack of correlation between HLA-C*06 and family history of psoriasis. Acta Derm Venereol. 2014;94: 667–671.
Zhang P, Su Y, Lu Q. Epigenetics and psoriasis. J Eur Acad Dermatol Venereol. 2012;26: 399–403.
Harden JL, Krueger JG, Bowcock AM. The immunogenetics of Psoriasis: A comprehensive review. J Autoimmun. 2015;64: 66–73.
Furue K, Yamamura K, Tsuji G, Mitoma C, Uchi H, Nakahara T, et al. Highlighting Interleukin-36 Signalling in Plaque Psoriasis and Pustular Psoriasis. Acta Derm Venereol. 2018;98: 5–13.
Müller A, Hennig A, Lorscheid S, Grondona P, Schulze-Osthoff K, Hailfinger S, et al. IκBζ is a key transcriptional regulator of IL-36-driven psoriasis-related gene expression in keratinocytes. Proc Natl Acad Sci U S A. 2018;115: 10088–10093.
Nguyen CM, Beroukhim K, Danesh MJ, Babikian A, Koo J, Leon A. The psychosocial impact of acne, vitiligo, and psoriasis: a review. Clin Cosmet Investig Dermatol. 2016;9: 383–392.
Koo JY, Do JH, Lee CS. Psychodermatology. J Am Acad Dermatol. 2000;43: 848–853.
Gordon KB, Armstrong AW, Han C, Foley P, Song M, Wasfi Y, et al. Anxiety and depression in patients with moderate-to-severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 study. J Eur Acad Dermatol Venereol. 2018;32: 1940–1949.
Kim GE, Seidler E, Kimball AB. Effect of Age at Diagnosis on Chronic Quality of Life and Long-Term Outcomes of Individuals with Psoriasis. Pediatr Dermatol. 2015;32: 656–662.
Kimball AB, Naegeli AN, Edson-Heredia E, Lin C-Y, Gaich C, Nikaï E, et al. Psychometric properties of the Itch Numeric Rating Scale in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2016;175: 157–162.
Lysell J, Tessma M, Nikamo P, Wahlgren C-F, Ståhle M. Clinical characterisation at onset of childhood psoriasis - a cross sectional study in Sweden. Acta Derm Venereol. 2015;95: 457–461.
Takeshita J, Grewal S, Langan SM, Mehta NN, Ogdie A, Van Voorhees AS, et al. Psoriasis and comorbid diseases: Implications for management. J Am Acad Dermatol. 2017;76: 393–403.
Londoño Á, González C, Castro L, Puig L. Psoriasis y su relación con el síndrome metabólico. Revista Colombiana de Reumatología. 2013;20: 228–236.
Bhushan R, Lebwohl MG, Gottlieb AB, Boyer K, Hamarstrom E, Korman NJ, et al. Translating psoriasis guidelines into practice: Important gaps revealed. J Am Acad Dermatol. 2016;74: 544–551.
Madrid Álvarez MB, Carretero Hernández G, González Quesada A, González Martín JM. Measurement of the Psychological Impact of Psoriasis on Patients Receiving Systemic Treatment. Actas Dermosifiliogr. 2018;109: 733–740.
Xia L, Li R, Wang Y, Lin Z, Zheng J, Li X, et al. Efficacy, safety, and cost-effectiveness of all-trans retinoic acid/Clobetasol Propionate Compound Ointment in the treatment of mild to moderate psoriasis vulgaris: A randomized, single-blind, multicenter clinical trial. Dermatol Ther. 2018;31: e12632.
Sticherling M, Augustin M, Boehncke W-H, Christophers E, Domm S, Gollnick H, et al. Therapy of psoriasis in childhood and adolescence - a German expert consensus. J Dtsch Dermatol Ges. 2011;9: 815–823.
Dickel H, Bruckner T, Altmeyer P. Long-term real-life safety profile and effectiveness of fumaric acid esters in psoriasis patients: a single-centre, retrospective, observational study. J Eur Acad Dermatol Venereol. 2018;32: 1710–1727.
Valenzuela F, Korman NJ, Bissonnette R, Bakos N, Tsai T-F, Harper MK, et al. Tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: long-term safety and efficacy in an open-label extension study. Br J Dermatol. 2018;179: 853–862.
van Geel MJ, Mul K, de Jager MEA, van de Kerkhof PCM, de Jong EMGJ, Seyger MMB. Systemic treatments in paediatric psoriasis: a systematic evidence-based update. J Eur Acad Dermatol Venereol. 2015;29: 425–437.
Paller AS, Siegfried EC, Pariser DM, Rice KC, Trivedi M, Iles J, et al. Long-term safety and efficacy of etanercept in children and adolescents with plaque psoriasis. J Am Acad Dermatol. 2016;74: 280–7.e1–3.
Horneff G, Seyger MMB, Arikan D, Kalabic J, Anderson JK, Lazar A, et al. Safety of Adalimumab in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, Psoriasis, and Crohn’s Disease. The Journal of Pediatrics. 2018. pp. 166–175.e3. doi:10.1016/j.jpeds.2018.05.042
Nast A, Spuls PI, van der Kraaij G, Gisondi P, Paul C, Ormerod AD, et al. European S3-Guideline on the systemic treatment of psoriasis vulgaris - Update Apremilast and Secukinumab - EDF in cooperation with EADV and IPC. Journal of the European Academy of Dermatology and Venereology. 2017. pp. 1951–1963. doi:10.1111/jdv.14454
Nast A, Gisondi P, Ormerod AD, Saiag P, Smith C, Spuls PI, et al. European S3-Guidelines on the systemic treatment of psoriasis vulgaris - Update 2015 - Short version - EDF in cooperation with EADV and IPC. Journal of the European Academy of Dermatology and Venereology. 2015. pp. 2277–2294. doi:10.1111/jdv.13354
Vilarrasa E, Notario J, Bordas X, López-Ferrer A, Gich IJ, Puig L. ORBIT (Outcome and Retention Rate of Biologic Treatments for Psoriasis): A retrospective observational study on biologic drug survival in daily practice. J Am Acad Dermatol. 2016;74: 1066–1072.
Batalla A, Fernández-Torres R, Rodríguez-Pazos L, Monteagudo B, Pardavila-Riveiro R, Rodríguez-Lojo R, et al. Systemic Treatment of Moderate to Severe Psoriasis in Pediatric Patients in Galicia, Spain: A Descriptive Study. Actas Dermosifiliogr. 2018;109: 722–732.
Coelho MMV, Apetato M. The dark side of the light: Phototherapy adverse effects. Clinics in Dermatology. 2016. pp. 556–562. doi:10.1016/j.clindermatol.2016.05.005
Valejo Coelho MM, Matos TR, Apetato M. The dark side of the light: mechanisms of photocarcinogenesis. Clin Dermatol. 2016;34: 563–570.
Munera-Campos M, Ballesca F, Carrascosa JM. Paradoxical Reactions to Biologic Therapy in Psoriasis: A Review of the Literature. Actas Dermosifiliogr. 2018;109: 791–800.
Effective use of ustekinumab in a patient with concomitant psoriasis, vitiligo, and alopecia areata. JAAD Case Reports. 2017;3: 477–479.
D D-SI-G, Moumdjian H. Uso de fototerapia en niños: nuestra experiencia. Revista de la Asociación Colombiana de Dermatología y Cirugía Dermatológica. 2020;28: 63–74.
Eustace K, Dolman S, Alsharqi A, Sharpe G, Parslew R. Use of Phototherapy in Children. Pediatr Dermatol. 2017;34: 150–155.
Crall CS, Rork JF, Delano S, Huang JT. Phototherapy in children: Considerations and indications. Clin Dermatol. 2016;34: 633–639.
Koo JYM, Menter A. The Koo-Menter Psoriasis Instrument for Identifying Candidate Patients for Systemic Therapy. Psoriasis Forum. 2003. pp. 6–9. doi:10.1177/247553030309a00205
Psoriasis y embarazo: revisión (II). Actas Dermo-Sifiliográficas. 2014;105: 813–821.
Downloads
Publicado
Edição
Seção
Licença
Este trabalho está licenciado sob uma licença Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
